علاج سرطان الغدد الليمفاوية الجريبي في المرحلة المتقدمة مع عبء ورمي منخفض وغياب الأعراض

References

DOI: 10.3390/cancers18030395

• For advanced stages with low tumor burden, observation is recommended (1A); however, rituximab monotherapy is also a valid option (1A).
• These patients may be managed with observation, including regular clinical and laboratory monitoring (1A).
• Therefore, for this patient group, both watchful waiting and rituximab monotherapy are considered appropriate options (1A).